Tranzyme Pharma announced that the FDA has granted fast track designation to its oral gastrointestinal (GI) prokinetic drug candidate TZP-102, for the treatment of gastroparesis in diabetic patients. Tranzyme is currently enrolling patients in a multi-national Phase 2, randomized, double-blind, placebo-controlled study of TZP-102. This study will evaluate the safety and efficacy of TZP-102 in accelerating gastric emptying and improving symptoms of gastroparesis in patients with diabetes mellitus (DM).
TZP-102 is an orally administered, prokinetic, second generation, agonist of the ghrelin receptor, which is distributed in both the upper and lower GI tract.
For more information call (919) 313-4760 or visit www.tranzyme.com.